Cancer – SC-4005: A Phase 1/2 Study of Pembrolizumab (MK-3475) in Children With Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE-051)
Condition or Therapy:
melanoma, lymphoma, solid tumor, classical Hodgkin lymphoma, microsatellite-instability-high solid tumor, pembrolizumab
Category:
Cancer and Blood Disorders
Study Number: SC-4005
What is the goal of this study?
The goal of this study is to evaluate the objective response rate, number of patients with dose-limiting toxicities and number of patients with adverse events for pembrolizumab therapy.
Who can join the study?
This study may be a good fit for children and young adults who:
- Are between 6 months and 17 years old, and
- Have a diagnosis of melanoma, lymphoma, solid tumor, classical Hodgkin lymphoma, or microsatellite-instability-high solid tumor
What will happen if my child takes part in this study?
You can read more about this study on clinicaltrials.gov.
Who can I contact for more information?
To learn more, call 206-987-2106 or email the study coordinator.
Study Location(s):
Seattle Children's Main Hospital Campus
Principal Investigator:
Dr. Navin Pinto
Research Center: Center for Clinical and Translational Research
